Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Gains from Investment Securities (2016 - 2026)

Heron Therapeutics filings provide 16 years of Gains from Investment Securities readings, the most recent being $219000.0 for Q1 2026.

  • On a quarterly basis, Gains from Investment Securities rose 544.12% to $219000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $219000.0, a 277.59% increase, with the full-year FY2025 number at $28.7 million, up 10.06% from a year prior.
  • Gains from Investment Securities hit $219000.0 in Q1 2026 for Heron Therapeutics, down from $28.7 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $5.5 billion in Q3 2023 to a low of $33000.0 in Q4 2023.
  • Median Gains from Investment Securities over the past 5 years was $9.7 million (2023), compared with a mean of $358.0 million.
  • Biggest five-year swings in Gains from Investment Securities: soared 78936.36% in 2024 and later plummeted 99.88% in 2025.
  • Heron Therapeutics' Gains from Investment Securities stood at $20.5 million in 2022, then plummeted by 99.84% to $33000.0 in 2023, then soared by 78936.36% to $26.1 million in 2024, then increased by 10.06% to $28.7 million in 2025, then tumbled by 99.24% to $219000.0 in 2026.
  • The last three reported values for Gains from Investment Securities were $219000.0 (Q1 2026), $28.7 million (Q4 2025), and $3.2 million (Q3 2025) per Business Quant data.